April 4th 2017: Emosis Ltd, BioRap Technologies and Rambam MedTech Ltd. to Collaborate on the Development of Novel Hypercoagulation Diagnostics Kit

TEL AVIV and HAIFA, Israel, April 4, 2017 /PRNewswire/ --

The diagnostics company Emosis Ltd., BioRap Technologies and Rambam MedTech Ltd, the technology transfer companies of the Rappaport Institute at the Technion - Israel Institute of Technology and Rambam Healthcare Campus, have entered into an exclusive license agreement to develop and commercialize hypercoagulation kit for several indications based on microparticles.

Prof. Benjamin Brenner and Prof. Anat Aharon from the Rappaport Institute and Rambam Healthcare Campus developed a proprietary technology enabling measurement of microparticles based biomarker for identifying and monitoring high risk patients who should be treated for coagulation complications.

Under the terms of the agreement, Emosis will use its know-how and IP to develop the biomarker(s) as a commercial kit. BioRap Technologies Ltd. and Rambam MedTech will perform some of the supporting research at the Rappaport Institute and Rambam Healthcare Campus.

"We are excited with the opportunity to collaborate with Emosis and jointly develop novel hypercoagulation kit based on these novel biomarkers. The kit is expected to predict potential thrombotic risk. Together, we hope to develop the kit that could help patients suffering from these side effects," commented Dr. Orit Shaked, Biorap Technologies CEO.

"The licensed technology perfectly matches Emosis ambition to develop cell-based hemostasis assays, and it complements very well our existing technology platform. This is especially of importance to assess blood clotting risk in cancer since microparticles of tumor origin increasingly appear as biomarkers of hypercoagulation in malignancies," added Dr. Frédéric Allemand, Board Member of Emosis Ltd.

"We are proud to partner with such prominent Israeli research institutions. This collaboration, especially on the intensively studied topic of microparticles, is a founding step for Emosis Ltd. and the development of our local R&D capabilities," commented Aurore André, CEO of Emosis Ltd.

The research team was led by Prof. Benjamin Brenner and Prof. Anat Aharon. Prof. Anat Aharon is the Head of the Microvesicle Research Laboratory that was established together with Prof. Brenner at the Rambam Health Care Campus. She is Assistant Professor at the Rappaport Faculty of Medicine of the Technion, Israel Institute of Technology in Haifa, Israel - and a member at the Clinical Research Institute at Rambam (CRIR).

About Emosis Ltd. 

Emosis Ltd is the affiliate of Emosis SAS, a French MedTech company founded early 2015 by Prof. Aaron Tomer and Dr. Frederic Allemand, to address largely unmet testing needs of patients presenting conditions associated with hemostasis and thrombosis disorders. Emosis uniquely applies, in a user-friendly way, the power of flow cytometry technology within the emerging paradigm of cell-based hemostasis, with a particular focus on microparticles for Emosis Ltd., to enlighten decision of the physicians managing those patients. Visit http://www.emosis-diagnostics.com and follow us on Linkedin

About Rambam MedTech 

Rambam MedTech is the technology transfer company for Rambam Healthcare Campus, and serves as the industrial liaison to bring medical innovations to market. Rambam Healthcare Campus is the largest academic hospital in Northern Israel and one of Israel's premiere hospitals, ​The company is aligned with the vision of Rambam to support the pioneering and innovative research of Rambam's physicians and scientists, transforming novel ideas into world class medical products. Visit http://www.rambammedtech.com

About BioRap Technologies at the Technion's Rappaport Institute for Research in Biomedical Sciences  

BioRap is the Rappaport Institute's technology transfer company and its liaison to industry, bringing promising scientific innovations generated at the Institute to collaboration with industry and commercialization. The company provides the legal and commercial frameworks for the inventions and innovations of RI researchers, protecting discoveries and innovations with patents, and working jointly with industry to bring scientific discovery to the market. For more information, visit http://www.bio-rap.com

Contact: Aurore André, CEO Emosis Ltd, +972-50-422-62-67, aurore.andre@emosis-diagnostics.com

SOURCE Emosis Ltd, BioRap Technologies Ltd and Rambam MedTech Ltd